


Convergent Stereospecific Total Synthesis of Monocillin I and Monorden (or Radicicol)

Maxime Lampilas and Robert Lett*

Unité Mixte CNRS - Roussel Uclaf (UMR 26)
BP 9 - 93230 Romainville (France)

Abstract : The first total syntheses of the antifungal resorcylic macrolides Monocillin I and Monorden (or Radicicol) have been achieved by a convergent stereospecific route. TBDMS phenol ethers were found to be suitable for all the scheme and were removed in the ultimate step under mild conditions (aqueous borax/THF/methanol), hence allowing to get the natural macrolides in good yields, with no degradation. An efficient conversion of di-OTBDMS Monocillin I into Monorden is also reported.

The mycotoxins Monocillin I **1**¹ and Monorden (or Radicicol) **2**^{1, 2} are 14 - membered resorcylic macrolides which have interesting pharmacological properties^{1 - 3}. Their structures only differ by the chlorine substitution⁴ and a recent X-ray study established the three asymmetric carbon atoms as having the *R* configuration^{2j}.




In the preceding communication, we reported a convergent stereospecific route to di-O-methyl derivatives related to Monocillin I⁵. The same strategy might also be applied for the preparation of monochiral related unnatural macrolides. However, one remaining difficulty was to find a suitable phenol protecting group, compatible with the reaction conditions and whose removal would not affect the highly sensitive natural macrolides, such as **1** and **2**^{2e}.


The synthesis of Monocillin I was achieved according to Scheme 1, using the palladium-catalyzed coupling of the di O-TBDMS chloromethyl isocoumarin **5** with the monochiral vinylstannane **7**^{5, 6}.

The isocoumarin **5** was obtained in 93% overall yield from **3**⁵, by demethylation with boron tribromide and then silylation in standard conditions. Noteworthy, complete halogen exchange occurs in situ in the silylation step, as shown by NMR and MS. Deprotection of the silyl ether **6**⁵ with $n\text{Bu}_4\text{N}^+$, F^- afforded **7** in 98% yield. The coupling of **5** (1.0eq) with **7** (1.1eq) was done in the same conditions as previously⁵ (3% mol PdCl_2 (CH_3CN)₂, 5% mol PPh_3 , DME reflux, argon), for **3** and **6**⁵, affording **8** in a good yield (75%).

Monocillin I synthesis (Scheme 1)



Monorden synthesis (Scheme 2)



References and notes:

1. Ayer W.A., Lee S.P., Tsuneda A., Hiratsuka Y., *Can. J. Microbiol.*, **1980**, *26*, 766.
2. a) Delmotte P., Delmotte-Plaquee J., *Nature*, **1953**, *171*, 344.
b) White N.H., Chilvers G.A., Evans G., *Nature*, **1962**, *195*, 406.
c) Mc Capra F., Scott A.I., Delmotte P., Delmotte-Plaquee J., Bhacca N.S., *Tetrahedron Lett.*, **1964**, 869.
d) Mirrington R.N., Ritchie E., Shoppee C.W., Taylor W.C., Sternhell S., *Tetrahedron Lett.*, **1964**, 365.
e) Mirrington R.N., Ritchie E., Shoppee C.W., Sternhell S., Taylor W.C., *Aust. J. Chem.*, **1966**, *19*, 1265.
f) Evans G., White N.H., *Trans. Br. Mycol. Soc.*, **1966**, *49*, 563.
g) Nozawa K., Nakajima S., *J. Nat. Prod.*, **1979**, *42*, 374.
h) Sigg H.P., Loeffler W., (Sandoz A.G.), US 3,428,526 (1969).
i) Espenshade M.A., Calton G.J., (W.R. Grace and Co.), Belg. 873,855, (1979), US Appl. 874,207, (1978).
j) Cutler H.G., Arrendale R.F., Springer J.P., Cole P.D., Roberts R.G., Hanlin R.T., *Agric.Biol.Chem.*, **1987**, *51*, 3331.
k) Nakajima H., Hamasaki T., Tanaka K., Kimura Y., Udagawa S., Horie Y., *Agric. Biol. Chem.*, **1989**, *53*, 2291.
l) Arai K., Shimizu S., Miyajima H., Yamamoto Y., *Chem. Pharm. Bull.*, **1989**, *37*, 2870.
3. a) Betina V., Micekova D., *Z. Allg. Mikrobiol.*, **1972**, *12*, 355.
b) Betina V., Micekova D., *Z. Allg. Mikrobiol.*, **1973**, *13*, 287.
c) Hrmova M., Drobnica L., *Mycopathologia*, **1982**, *79*, 55.
d) Sturdik E., Drobnica L., Sladkova V., Krchnava E., *Biologia*, **1983**, *38*, 1229.
e) Tsuneda A., Hiratsuka Y., *Phytopathology*, **1980**, *70*, 1101.
f) Calton G.J., (W.R. Grace and Co.), Belg. 873,856, (1979); US Appl. 874,348, (1978).
g) Horakova K., Betina V., *Neoplasma*, **1977**, *24*, 21.
4. Ayer W.A., Pena-Rodriguez L., *Phytochemistry*, **1987**, *26*, 1353.
5. a) Lampilas M., Lett R., preceeding communication.
b) Lampilas M., PhD thesis-Université Pierre et Marie Curie (PARIS-VI) (1991).
The isocoumarin **3** is prepared in 34 % overall yield from orcinol hydrate.
6. A pure diastereoisomer corresponding to the major condensation product of the monochiral epoxy aldehyde and *E*-tributylstannyl vinyl lithium was used throughout the complete scheme (configuration not determined at C-6').
7. Specific deprotection to yield **9** possibly occurs in the oxidation step either via an intramolecular nucleophilic attack at silicon by the carboxylate and further hydrolysis of the intermediate silyl ester, or by a general base catalysis involving the carboxylate. No migration of silyl group or desilylation occurs in the DIBAH reduction.
8. This identification also clearly demonstrates that a stereospecific inversion of configuration occurs in the Mitsunobu macrolactonisation step. No other diastereoisomeric lactone could be detected.

(Received in France 11 September 1991)